Cutting edge in Myasthenia Gravis

Autoimmunity Reviews

Volumn 12, Issue 9, 2013, Pages 861-862

  Berrih Aknin, Sonia ^a   Souroujon, Miriam C ^b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b OPEN UNIVERSITY OF ISRAEL   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CHOLINERGIC RECEPTOR ANTIBODY; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 4 ANTIBODY; MUSCLE SPECIFIC KINASE ANTIBODY; UNCLASSIFIED DRUG;

B LYMPHOCYTE; EDITORIAL; HUMAN; INNATE IMMUNITY; MYASTHENIA GRAVIS; NONHUMAN; POSTSYNAPTIC MEMBRANE; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; THYMOCYTE;

HUMANS; INFLAMMATION; MYASTHENIA GRAVIS; RECEPTORS, CHOLINERGIC; THYMUS GLAND;

EID: 84879152831     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2013.03.008     Document Type: Editorial

References (12)

1. Cavalcante P., Cufi P., Mantegazza R., Berrih-Aknin S., Bernasconi P., Le Panse R. Etiology of myasthenia gravis: Innate immunity signature in pathological thymus. Autoimmun Rev 2013, 12(9):863-874. (this issue).
2. Marx A., Pfister F., Schalke B., Saruhan-Direskeneli G., Melms A., Ströbel P. The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes. Autoimmun Rev 2013, 12(9):875-884. (this issue).
3. Berrih-Aknin S., Ragheb S., le Panse R., Lisak R.P. Ectopic germinal centers, BAFF and anti-B-cell therapy in myasthenia gravis. Autoimmun Rev 2013, 12(9):885-893. (this issue).
4. Gertel-Lapter S., Mizrachi K., Berrih-Aknin S., Fuchs S., Souroujon M.C. Impairment of regulatory T cells in myasthenia gravis: studies in an experimental model. Autoimmun Rev 2013, 12(9):894-903. (this issue).
5. Tüzün E., Christadoss P. Complement associated pathogenic mechanisms in myasthenia gravis. Autoimmun Rev 2013, 12(9):904-911. (this issue).
6. Mori S., Shigemoto K. Mechanisms associated with the pathogenicity of antibodies against muscle-specific kinase in myasthenia gravis. Autoimmun Rev 2013, 12(9):912-917. (this issue).
7. Verschuuren J.J.G.M., Huijbers M.G., Plomp J.J., Niks E.H., Molenaar P.C., Martinez-Martinez P., Gomez Alejandro M., De Baets M.H., Losen M. Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4. Autoimmun Rev 2013, 12(9):918-923. (this issue).
8. Hoch W., McConville J., Helms S., Newsom-Davis J., Melms A., Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001, 7:365-368.
9. Higuchi O., Hamuro J., Motomura M., Yamanashi Y. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol 2011, 69:418-422.
10. Zisimopoulou P., Brenner T., Trakas N., Tzartos S.J. Serological diagnostics in myasthenia gravis based on novel assays and recently identified antigens. Autoimmun Rev 2013, 12(9):924-930. (this issue).
11. Evoli A., Padua L. Diagnosis and therapy of myasthenia gravis with antibodies to muscle-specific kinase. Autoimmun Rev 2013, 12(9):931-935.
12. Dalakas M.C. Novel future therapeutic options in Myasthenia Gravis. Autoimmun Rev 2013, 12(9):936-941. (this issue).